New Oslo PSC biobank.  Broad consent – covers all clinical and research biobanking  Integrated storage of clinical data and biological material  DNA,

Slides:



Advertisements
Similar presentations
Specimen Model Project: Requirements from Clinical Genomics Mukesh Sharma Washington University Medical School St. Louis October 2010 WG meeting.
Advertisements

CP Incidence of Cholangiocarcinoma Cumulative incidence of cholangiocarcinoma (%) Years since PSC diagnosis CP
The Veterans Affairs Central Biorepository and MVP Highlights Mary T
The IndianaCTSI Biorepository is committed to serving the repository needs for CTSI investigators. The core will tailor specimen management to the needs.
Map interference lawyer - lawmaker. tree person(s) data associations implications relationships with others.
Registries, Databases & Clinical Networks David J Burn Newcastle University.
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
HISTOLOGICAL QUALITY CONTROL OF FROZEN SAMPLES USING MATCHING FFPE TISSUE – PRELIMINARY RESULTS OF OUR INSTITUTIONAL BIOBANK E. Mattioli, E. Foglia Manzillo,
Update on Cholangiocarcinoma: What we have learned from the International Hepatobiliary Neoplasia Biorepository Roon Chaiteerakij, MD Mayo Clinic, Rochester,
CALGB Fall Committee Meeting October 2006 Correlative Science Protocol Development Paula N. Friedman, PhD Director, Biospecimen & Correlative Science Operations.
Strategic Center for Clinical Cancer Research Clinical Cancer Research using Emerging Advanced Technologies for Health Title Slide.
XX Conference Seattle 2005 Consent and other legalities MedLawconsult.
Biostatistics ~ Types of Studies. Research classifications Observational vs. Experimental Observational – researcher collects info on attributes or measurements.
Environmental Health III. Epidemiology Shu-Chi Chang, Ph.D., P.E., P.A. Assistant Professor 1 and Division Chief 2 1 Department of Environmental Engineering.
Pregnancy Outcome Prediction Study University Department of Obstetrics and Gynaecology; PI – Professor Gordon CS Smith BACKGROUND The current pattern of.
Epigenetics of Celiac Disease MEDICEL Malta 2011.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
BIOC 401. Blood Sample To Detect Breast Cancer Cancer is actually a group of many related diseases that all have to do with cells. Cells are the very.
 Primary liver cancer is the fifth most common cancer in the world and the third most common cause of cancer mortality  Hepatocellular carcinomas (HCCs)
Clinical Trials The Way We Make Progress Against Disease.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Aging Cognition Evaluation A Unique Opportunity in understanding age related disorders.
Canadian Health Measures Survey (CHMS) Biobank Joanne Boisjoli Health Statistics Division Statistics Canada 1 Statistics Canada Statistique Canada.
Eleni Galani Medical Oncologist
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
INTRODUCTIE: PROFIEL EN FUNCTIE Biobank: opportunities, support and service models.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
Medicel (AOECS 2011) PATIENT FIRST – AT THE CENTER BIOBANKING Thomas M Attard MD FAAP FACG Associate Professor of Pediatrics, Physiology The University.
Treuman Katz Center for Pediatric Bioethics Conference Banking Biological Samples for Pediatric Research Jeffrey R. Botkin, M.D., M.P.H. Professor.
Zuo-Feng Zhang, MD, PhD Epi242, Prospective:  Cohort Studies: Observational studies  Intervention Studies, Clinical Trials  Nested Case-Control.
9/17/ Access WHI: Proposing Analyses and Ancillary Studies Andrea Z. LaCroix, PhD Professor of Epidemiology and Co-PI WHI Clinical Coordinating Center.
CCHMC’s Biobanking Software – James Morgan April 3, 2014 B iomaterial T racking & M anagement B iomaterial T racking & M anagement.
How to optimize the study design -
Mesothelioma Collections September 2010 through September 2011.
Radiation and Its Uses Pg Effects of Radiation Radioactive elements are potentially hazardous, but the effects are quite subtle The effects.
Prognose mittels Genexpression Prof. Martin H. Brutsche Kantonsspital St. Gallen-CH.
Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.
Chemicals for Life. Carbohydrates  Sugars and starch  C,H,O  Energy source.
Biobanks of Cerice Center for Gene Expression Research in Cancer Epidemiology Eiliv Lund, UiTø.
IndianaCTSI ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH Building an Indiana Biorepository Dave A Flockhart Eric Meslin April 19 th, 2010.
International PSC Study Group Meeting, Oslo, Jun 2010 Cholangiocarcinoma in PSC: Opportunities within a study group Dr Steve Pereira Institute of.
The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT.
Professor Bill Ollier Combining the strengths of UMIST and The Victoria University of Manchester.
Focus on NHS/Industry Morag McFarlane, PhD “World Leaders in Human Tissue Provision”
2011 NYU NMVB Report NYU Dept of Cardiothoracic Surgery NYU Dept of Pathology Monday November 7 th, 2011.
Handling and Evaluation 1. Handling and Evaluation of lung biopsies Understand methods 2. Understand methods for detection.
Dr. Jeyaparvathi Somasundaram
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
Bernedine Lund/Sue Mann 5/6/09.  Baseline—All participants ◦ Serum ◦ Plasma (citrate & EDTA) ◦ Buffy coat ◦ Red blood cells ◦ Urine (BMD subsample—3.
DNA STRUCTURE AND FUNCTION BIOLOGY. DNA FUNCTION DNA CONTAINS THE GENETIC INFORMATION THAT CODES FOR THE RNA AND PROTEINS NECESSARY FOR CELL FUNCTION.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
Facilitating tissue collection for translational research Jane Rogan Business Manager.
CaTissue Suite 1.2 TPBT Face to Face Michelle Lee, MBA, Ph.D. Ian Fore, D. Phil. December, 2009.
Zoe Ryan Carcinoembryonic Antigen (CEA). What is CEA? Carcinoembryonic antigen is a protein found in the blood of some adults who have certain cancers.
Available specimen depend on the stage and type of cancer Inoperable NSCLC (50%): here we have specimen from bronchoscopy (bronchial bx, brush cytology,
CaTissue Suite 1.2 TPBT Face to Face Michelle Lee, MBA, Ph.D. Ian Fore, D. Phil. December, 2009.
Neuroendocrine Tumour Biobank Dr Chrissie Thirlwell Cancer Research UK Clinician Scientist Senior Lecturer Medical Oncology Royal Free Hospital NET Unit.
The Bridge from Patient to Scientist Comparison: BioBank and Cancer Registry Data Source Distinct Patients Percent BioBank % Cancer Registry %
Cross-sectional studies
New research areas in personalised medicines
3. Bowel assays & crc risk:
Department of Microbiology
Baseline tumor biopsies
PPMI – GOALS 2019 Ken Marek PPMI Annual Meeting May 3, 2018
Epidemiology The science of associations.
Volume 25, Issue 3, Pages (March 2017)
Epidemiological Designs
Bilirubin.
UAB Tissue Biorepository
Presentation transcript:

New Oslo PSC biobank

 Broad consent – covers all clinical and research biobanking  Integrated storage of clinical data and biological material  DNA, RNA (blood), serum, plasma, cell-isolates  Biliary eptihelial cells (brushings), bile, intestinal biopsies  Fresh tissue at liver explantation, cancer tissue at resection  Standardized and written protocols all steps (SOP)  Regular QC of stored material  Barcode-based inventory system (-80°C/liquid nitrogen) New Oslo PSC biobank

Physical storage system

Database integration

Biobanking - background Norsk senter for PSC

Biobanks ?  Population banks  Biomarkers of susceptibility and population identity, and their operational substrate is germinal-line DNA from a huge number of healthy donors, representative of a concrete country/region or ethnic cohort  Disease-oriented banks for epidemiology  Biomarkers of exposure, using a huge number of samples, usually following a healthy exposed cohort/ case–control design studying germinal-line DNA or serum markers and a great amount of specifically designed and collected data.  Disease-oriented general biobanks (i.e. tumour banks)  Biomarkers of disease through prospective and/or retrospective collections of tumour and no-tumour samples and their derivates (DNA/RNA/ proteins), usually associated to clinical data and sometimes associated to clinical trials.  The amount of clinical data linked to the sample determinate the availability and biological value of the sample Norsk senter for PSC

Biobanking in PSC – why and how ?  Ethiopatogenesis  Serum/plasma samples  DNA-samples  Liver biopsies/ explanted liver  Bile duct cytology/biopsies  Colon biopsies: IBD+/-  Disease progression  Liver biopsies  Bile duct cytology/biopsies  Cholangiocancer  Tumor material  Dysplasia cytology Norsk senter for PSC

 Controversy: Competition vs. collaboration  Types of material?  Minimal level  Standardization (SOP)  study group website w/protocols?  Material exchange conditions  study group MTA ?  Study proposals  centers Biobanking in PSC:Discussion